149 related articles for article (PubMed ID: 37022947)
1. New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
Puglisi S; Calabrese A; Ferraù F; Violi MA; Laganà M; Grisanti S; Ceccato F; Scaroni C; Di Dalmazi G; Stigliano A; Altieri B; Canu L; Loli P; Pivonello R; Arvat E; Morelli V; Perotti P; Basile V; Berchialla P; Urru S; Fiori C; Porpiglia F; Berruti A; Pia A; Reimondo G; Cannavò S; Terzolo M
J Clin Endocrinol Metab; 2023 Sep; 108(10):2517-2525. PubMed ID: 37022947
[TBL] [Abstract][Full Text] [Related]
2. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series.
Kostiainen I; Hakaste L; Kejo P; Parviainen H; Laine T; Löyttyniemi E; Pennanen M; Arola J; Haglund C; Heiskanen I; Schalin-Jäntti C
Endocrine; 2019 Jul; 65(1):166-174. PubMed ID: 30980285
[TBL] [Abstract][Full Text] [Related]
3. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Tőke J; Uhlyarik A; Lohinszky J; Stark J; Huszty G; Micsik T; Borka K; Reismann P; Horányi J; Igaz P; Tóth M
Front Endocrinol (Lausanne); 2022; 13():952418. PubMed ID: 36246926
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
7. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
10. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
Beuschlein F; Weigel J; Saeger W; Kroiss M; Wild V; Daffara F; Libé R; Ardito A; Al Ghuzlan A; Quinkler M; Oßwald A; Ronchi CL; de Krijger R; Feelders RA; Waldmann J; Willenberg HS; Deutschbein T; Stell A; Reincke M; Papotti M; Baudin E; Tissier F; Haak HR; Loli P; Terzolo M; Allolio B; Müller HH; Fassnacht M
J Clin Endocrinol Metab; 2015 Mar; 100(3):841-9. PubMed ID: 25559399
[TBL] [Abstract][Full Text] [Related]
11. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
12. Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
Guelho D; Paiva I; Vieira A; Carrilho F
Endocrinol Nutr; 2016 May; 63(5):212-9. PubMed ID: 26969077
[TBL] [Abstract][Full Text] [Related]
13. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew E; Reiff E; Duh QY; Clark OH; McMillan A
World J Surg; 2006 May; 30(5):872-8. PubMed ID: 16680602
[TBL] [Abstract][Full Text] [Related]
14. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study.
Elhassan YS; Altieri B; Berhane S; Cosentini D; Calabrese A; Haissaguerre M; Kastelan D; Fragoso MCBV; Bertherat J; Al Ghuzlan A; Haak H; Boudina M; Canu L; Loli P; Sherlock M; Kimpel O; Laganà M; Sitch AJ; Kroiss M; Arlt W; Terzolo M; Berruti A; Deeks JJ; Libé R; Fassnacht M; Ronchi CL
Eur J Endocrinol; 2021 Nov; 186(1):25-36. PubMed ID: 34709200
[TBL] [Abstract][Full Text] [Related]
15. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
16. Management of adrenocortical carcinoma.
Strosberg JR; Hammer GD; Doherty GM
J Natl Compr Canc Netw; 2009 Jul; 7(7):752-8; quiz 759. PubMed ID: 19635227
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in adrenocortical carcinoma: data from a large Polish series.
Nowak KM; Samsel R; Cichocki A; Ambroziak U; Roszkowska-Purska K; Łebek-Szatańska A; Koperski Ł; Otto M; Zgliczyński W; Papierska L
Pol Arch Intern Med; 2018 Jun; 128(6):371-378. PubMed ID: 29726479
[TBL] [Abstract][Full Text] [Related]
18. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
19. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
[TBL] [Abstract][Full Text] [Related]
20. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
